Core Viewpoint - CalciMedica, Inc. has initiated an underwritten public offering of its common stock to support its clinical-stage biopharmaceutical development focused on CRAC channel inhibition therapies for inflammatory and immunologic diseases [1][2]. Company Overview - CalciMedica is a clinical-stage biopharmaceutical company that develops novel therapies targeting CRAC channels to modulate immune responses and protect against tissue cell injury [6]. - The company’s lead product candidate, Auxora™, has shown positive results in multiple clinical trials, including a Phase 2b trial for patients with acute pancreatitis and systemic inflammatory response syndrome (SIRS) [6]. - CalciMedica is conducting ongoing trials, including a Phase 2 trial for acute kidney injury (AKI) with data expected in 2025 [6]. Offering Details - The public offering will consist entirely of shares sold by the company, with a potential 30-day option for the underwriter to purchase an additional 15% of the shares [2]. - The offering is made under a shelf registration statement previously filed with the SEC, which was declared effective in August 2023 [4].
CalciMedica Announces Proposed Public Offering of Common Stock